Business / Finance

RSS

BIOREM first quarter revenue decreases 12.5% to $3,267,000

BIOREM Inc. announced today its results for the first quarter of 2012. Q1, 2012 revenue was $3,267,000, which is down $465,000 or 12.5% over the comparative period in the prior year.

31 May 2012

China Shenghuo first quarter total revenue increases 20.5% to $11.4M

China Shenghuo Pharmaceutical Holdings, Inc., today reported financial results for the first quarter ended March 31, 2012.

31 May 2012

AssureRx closes $12.5M Series C financing

AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.

31 May 2012

Medical imaging revenue market for CEE and Russia to reach $2.34 billion in 2015

Rising disease incidence and growing awareness about health issues will boost demand for medical imaging services across Central and Eastern Europe (CEE).

30 May 2012

RBCC negotiates potential joint venture with AMBS for traumatic brain injury treatment

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.

30 May 2012

Al Jazeera business program examines fight against malaria

Al Jazeera's "Counting the Cost" program on Saturday focused on the fight against malaria and the "business behind its treatment and prevention." According to the program, progress against malaria "is being threatened in these tough economic times. There is a $3 billion shortfall in funding for malaria treatment and prevention."

30 May 2012

Towers Watson acquires Extend Health

Towers Watson, a leading global professional services company, today announced the completion of its acquisition of Extend Health, Inc., which operates the largest private Medicare exchange in the United States.

30 May 2012

Partnership between Molecular Profiles and GEA Process Engineering to demonstrate benefits of new technology

Molecular Profiles, a leading specialist contract research and manufacturing organisation, announces that it has entered into a strategic collaboration with GEA Process Engineering - the company behind the world-recognized GEA Niro spray drying technology.

29 May 2012

Neovasc first quarter revenues increase 46% to $1,712,991

Neovasc Inc., today announced financial results for the three months ended March 31, 2012.

29 May 2012

Sonomax first quarter net revenue decreases to $149,726

Sonomax Technologies Inc. today disclosed its results for the three-month period ended March 31, 2012.

29 May 2012

Health Robotics announces HAT as new marketing and service channel in Saudi Arabia

Health Robotics today announced a new marketing and service channel for its world-leading i.v.STATION ONCO, i.v.SOFT, and i.v.STATION products with Kingdom of Saudi Arabia-based market leader Hospital Automation Technology (HAT). Health Robotics continues to spearhead the global healthcare industry and persisting on its worldwide quest to provide safe and cost-effective Intravenous Admixture Compounding Automation all over the world.

28 May 2012

Covalon second quarter revenue increases to $1,090,038

Mr. Brian Pedlar, President and CEO of Covalon Technologies Ltd., an advanced medical technologies company, is pleased to provide the following update.

28 May 2012

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration.

25 May 2012

Takeda signs agreement to acquire Multilab

Takeda Pharmaceutical Company Limited and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. today jointly announced that both parties have signed an agreement whereby Takeda Farmacêutica Brasil Ltda., a wholly-owned subsidiary of Takeda, aims to acquire Multilab.

25 May 2012

Halo Healthcare acquires assets of NeoMatrix

Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.

24 May 2012

APP expands portfolio of injectable critical care products

APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc.

24 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

Ventac and GIBH announce creation of CASiGEN Pharma

Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) today announced the creation of CASiGEN Pharma Ltd. (CASiGEN) to bring new treatments for diabetes and other metabolic disorders to the global market.

18 May 2012